ZS Oncology Value Watchdog Report: Biosimilars in Therapeutic Oncology

Christina Corridon

> Download

Biosimilars represent a disruptive new category of specialty drugs and there is significant speculation that oncology may uniquely adopt or accept them vs other therapeutic areas. Furthermore, biosimilars represent a vehicle and potential critical driver of value for the US market and beyond. Download the report for insight into the drivers and barriers of biosimilar adoption, ways that biosimilar manufacturers can differentiate, and top issues originators or next-generation product manufacturers should consider.


About the Expert

Christina Corridon is an Associate Principal in the Boston office and a leader in the ZS Oncology Practice. She has over a decade experience working in the pharmaceutical and biotech industries, with specific expertise in oncology and biosimilars. During her consulting career she has worked on US and global projects spanning commercialization strategy including launch strategy and planning, go-to market strategy, commercial models, marketing strategy and brand planning. Christina has an MPH in Health Policy and Management from the UCLA Fielding School of Public Health and an MBA from the Stern School of Business at New York University focused in Marketing. Christina completed her BA at Cornell University.                 

Contact ZS